2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169196
    D-687 2276762-06-0 98%
    D-687 is an inhibitor of Tau and Aβ. D-687 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties.
    D-687
  • HY-169197
    D-688 2276762-07-1 98%
    D-688 is an inhibitor of Tau and Aβ. D-688 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties. D-688 can improve the survival rate of Drosophila melanogaster expressing the human tau protein isoform (2N4R).
    D-688
  • HY-169215
    Anti-inflammatory agent 93 98%
    Anti-inflammatory agent 93 (compund 2g) is an imidazole derivative of Schiff base with analgesic and anti-inflammatory activities. Anti-inflammatory agent 93 targets COX-2 receptor and produces 89% analgesic efficacy in mice at 100 mg/kg.
    Anti-inflammatory agent 93
  • HY-169234
    BChE-IN-35 98%
    BChE-IN-35 (Azo-9) is a BChE inhibitor. BChE-IN-35 has a dynamic cis/trans conformational change, where the cis isomer preferentially binds to BChE. BChE-IN-35 can be used in Alzheimer's disease (AD) research.
    BChE-IN-35
  • HY-16923A
    Crobenetine hydrochloride 221018-88-8 98%
    Crobenetine hydrochloride (BIII-890 hydrochloride) is the hydrochloride form of Crobenetine (HY-16923). Crobenetine hydrochloride is a selective inhibitor for Na+ channel. Crobenetine hydrochloride displaces 3HBTX from site 2 of the Na+ channel (IC50=49 nM) in rat brain synaptosomes, exhibits only low binding affinity for other receptors and ion channels. Crobenetine hydrochloride protects brain tissue from the deleterious effects of focal cerebral ischemia in rodents.
    Crobenetine hydrochloride
  • HY-169263
    AC10142A 2963581-29-3 98%
    AC10142A is a selective Adenylyl Cyclase Type 1 inhibitor with IC50 of 0.26 μM. AC10142A can be used to study pain models.
    AC10142A
  • HY-169268
    Aβ-IN-10 98%
    Aβ-IN-10 (Compound Alz -5) is a bifunctional copper chelator and an inhibitor for beta-amyloid (Aβ), that interacts with Aβ aggregates and reduces the neurotoxicity. Aβ-IN-10 exhibits antioxidant efficacy, reveals moderate cytotoxicity with the presence of CuCl2 in SH-SY5Y and HepG2 with IC50 of 65.5, 31.2 μM. Aβ-IN-10 reduces the increase of cell stiffness caused by Aβ.
    Aβ-IN-10
  • HY-169287
    TriPEX-ClO4 98%
    TriPEX-ClO4 is a cationic fluorescent anticancer agent capable of BBB penetration. TriPEX-ClO4 can induces apoptosis and ferroptosis and can be used for study of cancer and brain diseases.
    TriPEX-ClO4
  • HY-169394
    5-HT1AR agonist 2 98%
    5-HT1AR agonist 2 (Compound 4f) is a 5-HT1A receptor agonist (Ki: 10.0 nM). 5-HT1AR agonist 2 also binds to the SERT, D2 receptor and 5-HT6 receptor (Ki: SERT, 2.8 nM; D2, 23 nM; 5-HT6, 192 nM). 5-HT1AR agonist 2 is stabilized in microsomes and induces hypothermia in mice.
    5-HT1AR agonist 2
  • HY-169432
    TET-13 98%
    TET-13 is a positive allosteric modulator of GABAA receptor with an EC50 of 5.65 μM, lower than that of Etomidate (EC50: 9.29 μM). TET-13 shows potent anesthetic effects in both mice and rats (ED50: 0.48 mg/kg and 0.69 mg/kg, respectively).
    TET-13
  • HY-169445
    (±)-Meclonazepam 67027-56-9 98%
    (±)-Meclonazepam ((±)-Ro 11-3128) is the racemate of Meclonazepam (HY-101725). Meclonazepam (Ro 11-3128) is a benzodiazepine compound with anxiolytic effect. Meclonazepam exhibits antischistosomal activity against S. mansoni.
    (±)-Meclonazepam
  • HY-169446
    ALEPH hydrochloride 61638-08-2 98%
    ALEPH (hydrochloride) is the h5-HT2A and h5-HT2B partial agonist with the EC50 values of 10.3 nM and 19.2 nM, respectively. ALEPH (hydrochloride) causes head twitch response in mice (ED50: 0.80 mg/kg).
    ALEPH hydrochloride
  • HY-169450
    (-)-9-Hydroxycorynantheidine 425623-55-8 98%
    (-)-9-Hydroxycorynantheidine (9-O-Desmethyl mitragynine), the 9-demethyl analogue of Mitragynine, is a selective and partial agonist of μ-opioid receptor. (-)-9-Hydroxycorynantheidine inhibits electrically stimulated twitch contraction in guinea-pig ileum.
    (-)-9-Hydroxycorynantheidine
  • HY-169451
    Cannabidiolic acid methyl ester 55658-71-4 98%
    Cannabidiolic acid methyl ester (HU-580) is an orally active cannabidiolic acid analogue. Cannabidiolic acid methyl ester can enhance the activation of 5-HT1A receptor and increase the expression of c-Fos and NeuN in specific hypothalamic nuclei of rats. Cannabidiolic acid methyl ester has anti-nausea, anti-anxiety and anti-injury effects.
    Cannabidiolic acid methyl ester
  • HY-169467
    5-Chloro-α-methyltryptamine 712-07-2 98%
    5-Chloro-α-methyltryptamine (Compound 7b) is a potent and selective dual DA/5-HT releaser and 5-HT2a agonist. 5-Chloro-α-methyltryptamine releases DA and 5-HT with the EC50 values of 54.3 nM and 16.2 nM, respectively. 5-Chloro-α-methyltryptamine can be used in the study of neurotransmitter.
    5-Chloro-α-methyltryptamine
  • HY-169470
    Pridinol hydrochloride 968-58-1 98%
    Pridinol hydrochloride is the hydrochloride salt form of Pridinol (HY-B1343A). Pridinol hydrochloride is an orally active anticholinergic agent, and acts as muscle relaxant.
    Pridinol hydrochloride
  • HY-169512
    MMB-4 2058-89-1 98%
    MMB-4 is an oxime that can reactivate cholinesterases that have been inactivated by exposure to organophosphates such as Sarin or Soman.
    MMB-4
  • HY-169557
    CDKI-IN-1 1185726-51-5 98%
    CDKI-IN-1 (Compound SNX12) is a cyclin-dependent kinase inhibitor (CDKI) inhibitor that can be used for research into degenerative diseases of the central nervous system.
    CDKI-IN-1
  • HY-169573
    Casein kinase 1δ-IN-16 851467-69-1 98%
    Casein kinase 1δ-IN-16 (compound 506) is a casein kinase 1δ (CK1δ) inhibitor. Casein kinase 1δ-IN-16 can be utilized in neurodegenerative disorders research.
    Casein kinase 1δ-IN-16
  • HY-169574
    Casein kinase 1δ-IN-17 450394-66-8 98%
    Casein kinase 1δ-IN-17 (compound 753) is a casein kinase 1δ (CK1δ) inhibitor. Casein kinase 1δ-IN-17 can be utilized in neurodegenerative disorders research.
    Casein kinase 1δ-IN-17
Cat. No. Product Name / Synonyms Application Reactivity